Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leniolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leniolisib SCHEMBL323054 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL323055 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30089313 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789521 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789551 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789594 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789520 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789519 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30767853 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29369662 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4709382-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITOR | Kura Oncology, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4704841-A1 | IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER | Eli Lilly and Company (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| CN-115607678-A | Combination therapy for the treatment of cancer | 杭州阿诺生物医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| WO-2022245820-A1 | VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| WO-2022143629-A1 | REAGENT AND METHOD FOR TREATING SKIN DISEASES OR CONDITIONS ASSOCIATED WITH ANTI-TUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| WO-2022111714-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | 杭州阿诺生物医药科技有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022076517-A1 | SUBJECT-SPECIFIC TREATMENTS FOR VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CD 2996/4885PIK3CA 2438/4885PIK3CB 3531/4885 |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | NOS2, NOS1, NOS3 | PIK3CD 3850/4885PIK3CA 3750/4885PIK3CB 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.